image: An image of blood samples being analyzed in a lab. view more
Credit: Public domain
Researchers have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease, according to a study published today in eLife.
Biomarkers are used to identify the state or risk of a disease in patients. Examples of biomarkers can include naturally occurring molecules or genes in the vascular, inflammatory or other biological pathways. The new findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.
Dengue is the most common mosquito-borne viral disease to affect humans globally. In 2019, the World Health Organization identified dengue as one of the top 10 threats to global health, with transmission occurring in 129 countries and an estimated 3.9 billion people being at risk.
"While most symptomatic dengue infections are self-limiting, a small number of patients develop complications that usually occur at around four to six days from symptom onset," explains first author Vuong Nguyen Lam, Researcher and PHD Student at Oxford University Clinical Research Unit (OUCRU), Ho Chi Minh City, Vietnam. "Large numbers of patients therefore need regular assessments to identify these complications. The accurate and early identification of such patients, particularly within the first three days of illness, should allow for the appropriate care to be provided."
The role of blood biomarkers in predicting severe outcomes has been investigated in other studies, but mostly later in the disease progression or at hospital admission. Many of these biomarkers either peak too late in the disease course or have too short a half-life to be clinically useful.
To address this, Vuong and colleagues selected 10 candidate biomarkers from vascular, immunological and inflammatory pathways that are associated with dengue disease pathogenesis. These biomarkers were: VCAM-1, SDC-1, Ang-2, IL-8, IP-10, IL-1RA, sCD163, sTREM-1, ferritin, and CRP. They were chosen based on their likelihood to be increased during the early stages of disease.
The team then conducted a study using samples and clinical information from a large multi-country observational study called 'Clinical evaluation of dengue and identification of risk factors for severe disease' (IDAMS study). Of the 2,694 laboratory-confirmed dengue cases included in the IDAMS study, 38 and 266 cases were classified as severe and moderate dengue, respectively.
For the current study, the researchers selected 281 cases in four countries - Vietnam, Cambodia, Malaysia and El Salvador - as the blood samples from these participants were stored at the OUCRU laboratory. For comparison, the team also selected 556 patients with uncomplicated dengue who shared similar geographies and demographic characteristics.
They measured the participants' blood biomarkers at two different time points - one during the first three days of illness, and the second following recovery (10-31 days after symptom onset). They found that, during the first three days of illness, higher levels of any of the 10 biomarkers increased a patient's risk of developing moderate to severe dengue.
They also identified a combination of six biomarkers that was best associated with severe disease in children, and a combination of seven biomarkers that was best associated with severe disease in adults. "This highlights how relationships between biomarkers and clinical outcome can differ between age groups," Vuong says.
"Together, our findings should assist the development of biomarker panels to help improve future triage and early assessment of dengue patients," concludes senior author Sophie Yacoub, Dengue Research Group Head at OUCRU. "This would help improve individual patient management and healthcare allocation, which would be of major public health benefit especially in outbreak settings."
###
Media contact
Emily Packer, Media Relations Manager
eLife
e.packer@elifesciences.org
+44 (0)1223 855373
About eLife
eLife is a non-profit organisation created by funders and led by researchers. Our mission is to accelerate discovery by operating a platform for research communication that encourages and recognises the most responsible behaviours. We aim to publish work of the highest standards and importance in all areas of biology and medicine, while exploring creative new ways to improve how research is assessed and published. eLife receives financial support and strategic guidance from the Howard Hughes Medical Institute, the Knut and Alice Wallenberg Foundation, the Max Planck Society and Wellcome. Learn more at https://elifesciences.org/about.
To read the latest research in Medicine published in eLife, visit https://elifesciences.org/subjects/medicine.
And for the latest in Microbiology and Infectious Disease, see https://elifesciences.org/subjects/microbiology-infectious-disease.
About OUCRU
The Oxford University Clinical Research Unit (OUCRU) is a large-scale clinical and public health research unit based in Vietnam, Indonesia and Nepal. Our strategic aim is to have a positive and significant impact on global health and, in particular, the prevention, diagnosis and treatment of infectious diseases. OUCRU is one of five Wellcome Trust Major Overseas Programmes. Together with our partners, we have led a highly successful effort in enhancing the infrastructure and capacity to perform clinical trials and basic scientific research in Vietnam, Indonesia and Nepal. Our 10-year vision is to have a local, regional and global impact on health by leading a locally-driven research programme on infectious diseases in Southeast Asia.